Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

With Three New Partnerships, Adimab Is On Track to Show Discovery Can Pay Off Quickly

This article was originally published in The Pink Sheet Daily

Executive Summary

A growing list of potentially lucrative partnerships has forced a strategic rethink at antibody discovery company Adimab, which plans to return cash to investors in 2011.

You may also be interested in...



Adimab Inks Novo, Biogen Deals, On Track to Double Partnered Programs for Second Straight Year

Antibody discovery outfit Adimab LLC has added two big biotechs to its stable of partners and promises a shift in partnering strategy for 2012.

Adimab Inks Novo, Biogen Deals, On Track to Double Partnered Programs for Second Straight Year

Antibody discovery outfit Adimab LLC has added two big biotechs to its stable of partners and promises a shift in partnering strategy for 2012.

Adimab Inks Merck, Roche Deals and Banks on the Value of Discovery

Adimab, the yeast-based antibody discovery biotech, has signed its first two alliances. In doing so the company revealed to Start-Up its partnering strategy, and discussed why it won't take a single step down the value chain into drug development. Can Adimab make discovery-only work where others have failed?

Topics

UsernamePublicRestriction

Register

PS071618

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel